Ürotelyal Karsinom Dışı Varyant Tip Mesane Kanserlerine Yaklaşım
Özet
Geleneksel ürotelyal karsinom dışı varyant tip mesane kanserleri (NÜMK), tüm mesane tümörlerinin yaklaşık %10'unu oluşturmakta ve genellikle enfeksiyon ile kronik inflamasyon kaynaklı epitel metaplazisinden gelişmektedir. Makroskopik hematüri ve irritatif işeme semptomları ile klinik veren bu nadir kanserler, klasik mesane kanserlerine kıyasla daha kötü prognoza ve daha yüksek nüks oranına sahiptir. Tanı, transüretral rezeksiyon (TUR-M) sonrası patolojik inceleme ile konulmaktadır. Başlıca histolojik alt tipler arasında skuamöz hücreli karsinom, adenokarsinom, küçük hücreli karsinom, sarkomlar, melanom ve lenfoma yer almaktadır. Skuamöz hücreli karsinom ve adenokarsinomun altın standart tedavisi radikal sistektomi iken; urakal tümörlerde ek cerrahi rezeksiyonlar ve spesifik kemoterapi rejimleri uygulanır. Agresif bir nöroendokrin tümör olan küçük hücreli karsinom, evreden bağımsız olarak neoadjuvan veya eş zamanlı kemoradyoterapi gerektirir. Sarkom ve melanom tipleri oldukça nadir ve kötü prognozlu olup cerrahi ağırlıklı multimodal tedavilerle yönetilirken, kronik sistit zemininde gelişen primer mesane lenfoması genellikle lokalizedir ve radyoterapiye iyi yanıt verir. Özetle, NÜMK türleri düşük görülme sıklığına rağmen agresif seyirlidir ve histolojik alt tipe göre özelleştirilmiş tedavi yaklaşımları gerektirmektedir.
Traditional non-urothelial variant type bladder cancers (NUBC) constitute approximately 10% of all bladder tumors and generally develop from epithelial metaplasia caused by infection and chronic inflammation. Presenting clinically with macroscopic hematuria and irritative voiding symptoms, these rare cancers exhibit a worse prognosis and higher recurrence rates compared to conventional bladder tumors. Diagnosis is established via pathological evaluation following transurethral resection (TUR-B). The primary histological subtypes include squamous cell carcinoma, adenocarcinoma, small cell carcinoma, sarcomas, melanoma, and lymphoma. While radical cystectomy remains the gold standard treatment for squamous cell carcinoma and adenocarcinoma, urachal tumors require additional surgical resections and specific chemotherapy regimens. Small cell carcinoma, which is an aggressive neuroendocrine tumor, necessitates neoadjuvant or concurrent chemoradiotherapy regardless of the stage. Sarcomas and melanomas are exceedingly rare with a poor prognosis, managed primarily through surgery-based multimodal treatments, whereas primary bladder lymphoma arising from chronic cystitis is typically localized and responds well to radiotherapy. In summary, despite their low incidence, NUBC variants follow an aggressive course and require customized therapeutic approaches tailored to their histological subtypes.
Referanslar
Billis A, Schenka AA, Ramos CC, et al. Squamous and/or glandular differentiation in urothelial carcinoma: prevalence and significance in transurethral resections of the bladder. Int Urol Nephrol. 2001;33: 631–633
Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol 2016;70:93-105.
Humphrey PA, Moch H, Cubilla AL, et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol 2016;70:106-119
Johnson DE, Schoenwald MB, Ayala AG, et al. Squamous cell carcinoma of the bladder. J Urol 1976;115(5):542–544
El-Sebaie M, Zaghloul MS, Howard G, et al. Squamous cell carcinoma of the bilharzial and non-bilharzial urinary bladder: a review of etiological features, natural history, and management. Int J Clin Oncol. 2005;10: 20–25
Kantor AF, Hartge P, Hoover RN, et al. Epidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladder. Cancer Res. 1988;48: 3853–3855.
Blochin EB, Park KJ, Tickoo SK, et al. Urothelial carcinoma with prominent squamous differentiation in the setting of neurogenic bladder: role of human papillomavirus infection. Mod Pathol 2012;25(11):1534–1542
Sheaf M, Jenkins BJ. Squamous cell carcinoma of the bladder following radiotherapy for transitional cell carcinoma. Br J Urol 1994; 74(1):131–132
Stein JP, Skinner EC, Boyd SD, et al. Squamous cell carcinoma of the bladder associated with cyclophosphamide therapy for Wegener’s granulomatosis: a report of 2 cases. J Urol 1993;149(3):588–589
Rundle JS, Hart AJ, McGeorge A, et al. Squamous cell carcinoma of bladder. A review of 114 patients. Br J Urol 1982;54(5):522–526
El-Boulkany MN, Ghoneim MA, Mansour MA. Carcinoma of the bilharzial bladder in Egypt. Clinical and pathological features. Br J Urol. 1972;44(5):561–570
Ghoneim MA, El-Mekresh MM, El-Baz MA, et al. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J Urol. 1997;158(2):393–399
Galsky M, Iasonos A, Mironov S, et al. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology 2007;69:255-259.
Swanson DA, Liles A, Zagars GK. Preoperative irradiation and radical cystectomy for stages T2 and T3 squamous cell carcinoma of the bladder. J Urol. 1990 Jan;143(1):37-40.
Zaghloul MS, Awwad HK, Akoush HH, et al. Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control. Int J Radiat Oncol Biol Phys 1992;23:511-517.
Thorn M, Bergstrom R, Johansson AM, et al. Trends in urinary bladder cancer incidence in Sweden 1960-93 with special reference to histopathology, time period birth cohort, and smoking. Cancer Causes Control. 1997;8: 5
Smeulders N, Woodhouse CR. Neoplasia in adult exstrophy patients. BJU Int 2001;87(7):623–628
Young RH, Scully RE. Clear cell adenocarcinoma of the bladder and urethra. A report of three cases and review of the literature. Am J Surg Pathol 1985;9(11):816–826
Türkölmez K. (2007). Mesanenin değişici epitel dışı kanserlerinde tanı ve tedavi. Özen H, Türkeri L. (Eds). Üroonkoloji kitabı içinde (s.375-387). Ankara: Ertem Basım
Abol-Enein H, Kava BR, Carmack AJK. Nonurothelial cancer of the bladder. Urology. 2007;69: 93–104.
Nabil Ismaili. A rare bladder cancer – small cell carcinoma: review and update. Journal of Dare Diseases. 2011;6: 1-11.
Siefker-Radtke AO, Kamat AM, Grossman HB, et al. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/ cisplatin in small-cell urothelial cancer. J Clin Oncol 2009; 27:2592-2597.
Siefker-Radtke AO, Dinney CP, Abrahams NA, et al. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: A retrospective review of the M. D. Anderson cancer experience. J Urol 2004;172:481-484.
Parekh DJ, Jung C, O’Conner J, et al. Leiomyosarcoma in urinary bladder after cyclophosphamide therapy for retinoblastoma and review of bladder sarcomas. Urology 2002;60(1):164
Russo P, Brady MS, Conlon K et al. Adult urological sarcoma. J Urol. 1992;147(4):1032–1036
Patil RV, Woldu SL, Lucas E, et al. Metastatic melanoma to the bladder: case report and review of the literature. Urol Case Rep 2017,11:33–36
Karabulut YY, Erdogan S, Sayar H, et al. Primary malignant melanoma of the urinary bladder: clinical, morphological, and molecular analysis of five cases. Melanoma Res 2016,26(6):616–624
Schniederjan SD, Osunkoya AO. Lymphoid neoplasms of the urinary tract and male genital organs: a clinicopathological study of 40 cases. Mod Pathol 2009;22(8):1057–1065 60.
Al-Maghrabi J, Kamel-Reid S, Jewett M, et al. Primary low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type arising in the urinary bladder: report of 4 cases with molecular genetic analysis. Arch Pathol Lab Med 2001;125(3):332–336 61.
Kempton CL, Kurtin PJ, Inwards DJ, et al. Malignant lymphoma of the bladder: evidence from 36 cases that low-grade lymphoma of the MALT-type is the most common primary bladder lymphoma. Am J Surg Pathol 1997;21(11):1324–1333
